{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-020517","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2026-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.502250+00:00","generated_at":"2026-05-15T09:24:06.162874+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Context Therapeutics releases updated corporate presentation focused on T cell engagers for solid tumors","bullets":["Presentation updated March 23, 2026 for investor and analyst meetings.","Slides emphasize advancing T cell engager platform for solid tumors; no financial or clinical data disclosed.","Slides 15 and 32 incorporated into Item 8.01, but specific content not detailed in filing.","Previous presentation replaced; no new pipeline milestones, partnerships, or financing announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-020517","json":"https://secwatch.observer/filing/0001628280-26-020517.json","markdown":"https://secwatch.observer/filing/0001628280-26-020517.md","text":"https://secwatch.observer/filing/0001628280-26-020517.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000162828026020517/0001628280-26-020517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000162828026020517/cntx-20260323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:24:06.162874+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}